Stage II Breast Cancer: Wendi's Survivor Story

Patient Info: Wendi Kushner | Stage II

Biomarkers: Triple-positive

After the clinical trial, lumpectomy pathology showed a complete pathological response with no residual cancer in the breast or lymph nodes.

MD AndersonRead more →

Stage IV lung adenocarcinoma discovered after recurrent pulmonary embolism

Patient Info: Anonymized, Male, Under 40 | Stage IV

Metastatic Site: bone

At 1-month follow-up, he remained on alectinib, tumor markers were declining, and pulmonary embolism had not recurred.

PubMed CentralRead more →

Hidden metastatic breast cancer found in bone marrow during blood-cancer monitoring

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: ER-positive

Metastatic Site: bone marrow, bone

More than 7 years after metastatic breast carcinoma was first identified in 2018, she had stable skeletal disease and ongoing biochemical improvement on palbociclib plus fulvestrant in March 2026.

PubMed CentralRead more →

RET-positive Stage IV lung cancer: targeted therapy stopped after severe side effects

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: RET fusion

Metastatic Site: brain|bone

Selpercatinib produced early shrinkage of the lung tumor and brain metastases, but it was permanently discontinued because of recurrent severe side effects. She was transferred for supportive care.

PubMed CentralRead more →

Stable Stage IV breast cancer after a serious side effect from abemaciclib

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: bone marrow

About 2 years after starting treatment, she remained on reduced-dose abemaciclib without disease progression.

PubMed CentralRead more →

Ovarian Cancer: Robyn's Survivor Story

Patient Info: Robyn Townsend

After surgery, 6 rounds of chemotherapy and ongoing olaparib, she reported no evidence of disease since the previous December.

MD AndersonRead more →

Stage IV Breast Cancer: Betty's Patient Story

Patient Info: Betty Jean, Female | Stage IV

Metastatic Site: Spine; ribs; liver

As of June 2026, Betty Jean was living with Stage IV metastatic breast cancer after bone involvement in the spine/ribs and later progression to the liver, with treatment including targeted therapy, radiation, and chemotherapy.

The Patient StoryRead more →

HER2-mutated lung cancer: restarting targeted therapy after lung inflammation

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: HER2 exon 20 insertion; PD-L1 negative

Metastatic Site: brain

Trastuzumab deruxtecan was restarted successfully after lung inflammation improved, but it was discontinued after 9 cycles when the cancer progressed.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Rosee's Patient Story

Patient Info: Rosee, Female | Stage IV

Biomarkers: EGFR mutation; specific variant not reported

Metastatic Site: brain

Within weeks of starting osimertinib, Rosee’s tumors shrank significantly, migraines and vertigo resolved, and hearing began to return; she remained on treatment and active in advocacy.

Lung Cancer Research FoundationRead more →

Stage IVA EGFR-mutant lung adenocarcinoma: clonal evolution, chemoimmunotherapy response, osimertinib rechallenge, and death after progression

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Markers changed over time: started with EGFR L747S/L858R; later MET-amplified, PD-L1 TPS 80%, high TMB clone; later EGFR reappeared.

Metastatic Site: pleura, peritoneal nodule, retroperitoneal lymph nodes

The patient died on 30 April 2025 after progression through multiple lines and infection related to treatment-associated myelosuppression.

PubMed CentralRead more →

Stage IV EGFR Lung Cancer: Shannon's Survivor Story

Patient Info: Shannon, Female, Under 40 | Stage IV

Biomarkers: EGFR mutation; TP53 mutation

Metastatic Site: cervical spine (C1/C2 and C4/C6), liver

As of June 2026, Shannon described no evidence of active disease: visible tumors were gone, the original lung mass had decreased from 10.8 cm to a 3.8 cm cavity, and targeted therapy continued to suppress possible remaining cells.

The Patient StoryRead more →

Long-term complete response to targeted therapy for relapsed lung cancer with an EGFR mutation

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: EGFR mutation

Her three most recent scans showed a complete response, and nearly 4 years after relapse she remained free of tumor progression while continuing targeted therapy.

PubMed CentralRead more →

Extensive-stage small cell lung cancer: multi-line treatment complicated by glucocorticoid-refractory immune-related cystitis

Patient Info: Anonymized, Male, 50s

Biomarkers: No molecular biomarkers reported for SCLC. Bladder biopsy during cystitis showed mostly CD3/CD8-positive T-cell inflammation.

As of December 2025, the cancer had progressed through multiple systemic lines, new brain metastasis had appeared, and care had shifted to palliative symptomatic treatment; immune-related cystitis had resolved after prednisone plus mycophenolate mofetil.

PubMed CentralRead more →

Stage IV EGFR-mutated lung adenocarcinoma: high-dose furmonertinib after CNS progression

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial EGFR L858R mutation. Later blood testing showed EGFR p.S553Y variation; CEA rose and fell with treatment.

Metastatic Site: brain/meninges; bilateral pleura/lungs; mediastinal…

As of June-September 2024, the left lung lesion was stable to slightly smaller on escalated furmonertinib, but brain/CNS lesions had progressed and required dose escalation to 240 mg/day; later imaging was declined.

PubMed CentralRead more →

Stage IV Breast Cancer: Bethany's Patient Story

Patient Info: Bethany W., Female, Under 40 | Stage IV

Metastatic Site: Bones; liver; lymph nodes; stomach

As of June 2026, Bethany was living with Stage IV metastatic breast cancer and responding well to maintenance treatment, with scans described as phenomenal and disease areas shrinking or disappearing.

The Patient StoryRead more →

Targeted treatment for an 89-year-old woman with Stage IV HRD-positive ovarian cancer

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: HRD-positive; germline BRCA2 pathogenic variant

Follow-up imaging showed a partial response, tumor markers improved, and she remained on treatment with better appetite and general condition at 7 months.

PubMed CentralRead more →

Stage III HER2-Positive Breast Cancer: Genoa's Survivor Story

Patient Info: Genoa M., Female | Stage III

Biomarkers: HER2-positive; ER-positive

As of June 2026, Genoa had completed treatment for Stage III HER2-positive, ER-positive breast cancer with neoadjuvant Taxotere/carboplatin/trastuzumab, lumpectomy, and radiation, and was focused on survivorship and rebuilding life after treatment.

The Patient StoryRead more →

Stage IV HER2-Positive Invasive Ductal Carcinoma: Renee's Patient Story

Patient Info: Renee N., Female | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Brain

As of June 2026, Renee’s public story described living with metastatic HER2-positive breast cancer as a chronic illness, after brain radiation and while on Kadcyla every 3 weeks with stable scans reported in December 2019 and early March 2020.

The Patient StoryRead more →

Stage II HR-Positive Breast Cancer: Rach's Patient Story

Patient Info: Rach D., Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of June 2026, Rach described Stage II triple-positive breast cancer treated with fertility preservation, 6 rounds of neoadjuvant TCHP including Herceptin, Zoladex ovarian suppression, and double mastectomy with reconstruction.

The Patient StoryRead more →

Stage IV ALK Lung Cancer: Nancee's Patient Story

Patient Info: Nancee Pronsati, Female | Stage IV

Biomarkers: ALK-positive; ALK fusion/rearrangement

Metastatic Site: bilateral lung nodules, brain

As of May 2026, Nancee had lived about 10 years with metastatic ALK-positive lung cancer, including brain progression, and continued long-term targeted therapy with quality of life as a major goal.

The Patient StoryRead more →

Stage IV Colorectal Cancer: Ken's Patient Story

Patient Info: Ken, Male, 50s | Stage IV

Metastatic Site: Liver

As of May 2026, Ken was more than 3 years into Stage IV colorectal cancer. He was not cancer-free or NED, but described the disease as minimal and manageable with surveillance, maintenance chemotherapy/targeted therapy, and occasional ablation.

The Patient StoryRead more →

Stage IV Non-Small Cell Lung Cancer: Jill's Patient Story

Patient Info: Jill, Female, 50s | Stage IV

Biomarkers: Driver mutation identified; specific mutation not stated

Metastatic Site: pleura

As of May 2026, Jill had lived 17 years with NSCLC, later experienced pleural metastases/progression, and remained on biomarker-guided targeted therapy with chemotherapy added.

The Patient StoryRead more →

EGFR-mutated Stage IV lung cancer with later brain progression

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR C797S mutation; acquired ROS1 rearrangement

Metastatic Site: brain|bone

She died about 20 months after diagnosis after brain progression and a severe postoperative stroke.

PubMed CentralRead more →

EGFR-mutated lung cancer responds after acquired ROS1 resistance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR L858R mutation; acquired ROS1 rearrangement

Metastatic Site: pleura

She remained on osimertinib plus crizotinib with a sustained clinical and radiologic response for more than 18 months.

PubMed CentralRead more →